LABT Stock Forecast: Lakewood-Amedex Biotherapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Lakewood-Amedex Biotherapeutics, Inc. is $7.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 17 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Lakewood-Amedex Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (80): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (1): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
LABT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on LABT, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Oct 2026 | HC Wainwright & Co. | Initiates | Buy | $3.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LABT.
This page is one stock. Monday covers all of them.
LABT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
LABT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.3×
- EV / EBITDA
- —
Cheaper than 91% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −833.7%
- Return on assets
- −188.2%
- Dividend yield
- —
Higher than 2% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Lakewood-Amedex Biotherapeutics, Inc. has a market value of $2.1M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$7.3M.
Free cash flow in the twelve months to 30 June 2026: −$3.5M.
Lakewood-Amedex Biotherapeutics, Inc. employs 5 people.
Data provided by Twelve Data
LABT and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at LABT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Lakewood-Amedex Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about LABT
What is the LABT stock price forecast for 2026-2027?
The median 12-month analyst price target for Lakewood-Amedex Biotherapeutics, Inc. is $7.5, with estimates ranging from $3 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is LABT stock a buy right now?
Of the 1 analyst covering Lakewood-Amedex Biotherapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lakewood-Amedex Biotherapeutics, Inc. 17 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank LABT?
As at 21 Nov 2026, Lakewood-Amedex Biotherapeutics, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (80 of 100).
Will LABT stock go up?
No one can know that. What the data says: the median 12-month target from 1 analyst is $7.5, and Ticker Nerd's factor model ranks Lakewood-Amedex Biotherapeutics, Inc. 17 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the LABT stock forecast for 2030?
No analyst covering Lakewood-Amedex Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LABT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $12 over the next 12 months.
What does Lakewood-Amedex Biotherapeutics, Inc. do?
Lakewood-Amedex Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing antimicrobial therapies for infectious diseases. Its current pipeline centers on the Bisphosphocin class, a novel group of broad-spectrum antimicrobials designed to address infections affecting the skin, bladder, lungs, and other serious bacterial conditions.
About Lakewood-Amedex Biotherapeutics, Inc.
Lakewood-Amedex Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing antimicrobial therapies for infectious diseases. Its current pipeline centers on the Bisphosphocin class, a novel group of broad-spectrum antimicrobials designed to address infections affecting the skin, bladder, lungs, and other serious bacterial conditions. The company’s lead program, Nu-3, is a topical antimicrobial being developed for infected diabetic foot ulcers, reflecting its emphasis on localized treatment options for hard-to-treat infections. Lakewood-Amedex Biotherapeutics also works on broader anti-infective applications aimed at antibiotic-resistant pathogens, positioning the company within the specialized biotechnology segment of the healthcare market. Headquartered in University Park, Florida, the company operates as a focused developer of next-generation antimicrobial products for unmet medical needs.
CEO Dr. Kelvin Cooper Ph.D. · 5 employees · United States · https://lakewoodamedex.com